Dr. Berdeja on Updated Data With bb21217 in Multiple Myeloma

March 31, 2020
Jesus Berdeja, MD

Partner | Cancer Centers | <b>Sarah Cannon</b>

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses updated data with bb21217 in multiple myeloma.

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses updated data with bb21217 in multiple myeloma.

In the dose-escalation portion of the phase I CRB-402 trial, patients with relapsed/refractory disease received 150 x 106 (n = 12), 300 x 106 (n = 6), and 450 x 106 (n = 6) CAR + T cells. Investigators also evaluated an expansion cohort to further explore the 300 x 106 (n = 8) and 450 x 106 doses (n = 6). Patients who received the 150 x 106 dose of bb21217 experienced an objective response rate (ORR) of 83%. Moreover, the CAR T cells persisted up to 18 months, says Berdeja.

The data in the other 2 cohorts had relatively short follow-up at the time of data cutoff. However, the ORRs ranged from 40% to 60%, says Berdeja. Notably, among the patients in these cohorts who experienced confirmed responses, none have experienced disease progression.


x